CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
- Status
- COMPLETED
- Phase
- N/A
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
- Status
- COMPLETED
- Phase
- N/A
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Scalp Cooling in MBC
- Status
- RECRUITING
- Phase
- PHASE2
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
- Status
- WITHDRAWN
- Phase
- NA
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
- Status
- COMPLETED
- Phase
- N/A
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Fulvestrant + Neratinib In Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
- Status
- WITHDRAWN
- Phase
- N/A
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3